A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed

Conditions studied: COPD, Pulmonary Disease, Chronic Obstructive

In brief

The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD. Patients must have received at least 1 dose of study agent (ie, placebo or infliximab) in the primary studies to be eligible for participation in this long-term follow-up study. Information on deaths and cancers will be collected twice yearly for a period of 5 years from each patient's last safety visit in the primary study.

Key facts

Study ID

NCT00380796

Run by

Centocor, Inc.

People needed

88

Starts

2006-04-01

Expected to finish

2009-12-01

Last updated by the study team

2013-09-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have been enrolled in previously completed clinical studies of infliximab in the treatment of COPD that are targeted for long term safety follow-up (ie, primary studies). Primary studies are defined as studies that have evaluated infliximab on an investigational basis and that have been identified by Centocor or health authorities as requiring long-term safety follow-up. These include Centocor protocol C0168T54, conducted in the USA, and 2 smaller studies conducted in the Netherlands (EU0016 C0168X09 and EU0073 C0168X57). Patients must have received at least one dose of study agent to be eligible.

You may not qualify if…

• Patients who are unwilling to respond to requests for long-term safety information will be excluded.

Where it is running

• Study site — Anaheim, California, United States
• Study site — San Diego, California, United States
• Study site — Bay Pines, Florida, United States
• Study site — Clearwater, Florida, United States
• Study site — Blue Ridge, Georgia, United States
• Study site — Baltimore, Maryland, United States
• Study site — Springfield, Massachusetts, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Saint Charles, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Omaha, Nebraska, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — Endwell, New York, United States
• Study site — Larchmont, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Easton, Pennsylvania, United States
• Study site — Hershey, Pennsylvania, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Greer, South Carolina, United States
• Study site — Spartanburg, South Carolina, United States
• Study site — Amarillo, Texas, United States
• Study site — Dallas, Texas, United States
• Study site — Salem, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.